Nokia CorporationInside information22 July 2025 at 19:00 EESTInside Information: Nokia lowers 2025 operating profit guidance due to currency   Nokia lowers its comparable operating profit guidance range to EUR 1.6 billion to EUR 2.1 billion from EUR 1.9 billion to EUR 2.4 billion.  Adjustment relates to currency headwinds from the weaker USD and tariffs. Reports preliminary Q2 financial results of approximately EUR 4.55 billion net sales and EUR 0.3 billion comparable operating profit.   Espoo, Finland – No ...

Core Points - Columbus A/S has adjusted its full-year financial guidance for 2025 due to a challenging macro-economic environment impacting customer decision-making on major IT projects, leading to project postponements and extended sales processes [1][2] - The revenue guidance has been revised from an expected organic growth of 7-9% to approximately the same level as 2024, which is DKK 1.7 billion [4] - The EBITDA margin guidance has been adjusted from an expected range of 10-12% to a new expected range of 7-9% [4] Upcoming Events - Columbus will release its Interim Report for Q2 2025 on August 21, 2025, providing further details on performance, and will host a teleconference for investors and analysts on the same day at 13:00 pm CET [3]

Core Insights - Ionis Pharmaceuticals reported a first-quarter EPS loss of 93 cents, an improvement from a loss of 98 cents, and better than the consensus estimate of a $1.12 loss [1] - Revenue for the first quarter of 2025 increased by 10% to $132 million, surpassing the consensus of $125.32 million, driven by higher commercial revenue [1] Financial Guidance - The company raised its 2025 revenue guidance by over 20% to a range of $725-$750 million, compared to previous guidance of over $600 million and the consensus of $659.37 million [4] - Ionis expects a 2025 adjusted operating loss of less than $375 million, improved from prior guidance of less than $495 million, with cash and equivalents projected at approximately $1.9 billion [4] Product Performance - The drug Tryngolza (olezarsen) generated over $6 million in net product sales in its first full quarter post-approval in the U.S. [6] - Wainua (eplontersen) for polyneuropathy generated $39 million in sales, resulting in $9 million in royalty revenue for the first quarter of 2025 [6] - Spinraza (nusinersen) for spinal muscular atrophy achieved global sales of $424 million, leading to $48 million in royalty revenue in the first quarter of 2025 [6]